Aoxing Pharmaceutical Company (AOXG) Ratios

37 Followers

Aoxing Pharmaceutical Company Ratios

AOXG's free cash flow for Q2 2026 was $0.99. For the 2026 fiscal year, AOXG's free cash flow was decreased by $ and operating cash flow was $-0.65. See a summary of the company’s cash flow.

Ratios	TTM	Jun 23	Jun 22	Jun 21	Jun 20
Liquidity Ratios
Current Ratio	0.96	0.00	0.00	0.00	0.00
Quick Ratio	0.96	0.00	0.00	0.00	0.00
Cash Ratio	0.18	0.00	0.00	0.00	0.00
Solvency Ratio	-0.18	0.00	0.00	0.00	0.00
Operating Cash Flow Ratio	-0.78	0.00	0.00	0.00	0.00
Short-Term Operating Cash Flow Coverage	-1.00	0.00	0.00	0.00	0.00
Net Current Asset Value	$ -5.47K	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Leverage Ratios
Debt-to-Assets Ratio	0.82	0.00	0.00	0.00	0.00
Debt-to-Equity Ratio	-18.82	0.00	0.00	0.00	0.00
Debt-to-Capital Ratio	1.06	0.00	0.00	0.00	0.00
Long-Term Debt-to-Capital Ratio	0.00	0.00	0.00	0.00	0.00
Financial Leverage Ratio	-23.03	0.00	0.00	0.00	0.00
Debt Service Coverage Ratio	-0.22	0.00	0.00	0.00	0.00
Interest Coverage Ratio	-54.35	0.00	0.00	0.00	0.00
Debt to Market Cap	0.12	0.00	0.00	0.00	0.00
Interest Debt Per Share	<0.01	0.00	0.00	0.00	0.00
Net Debt to EBITDA	-3.42	0.00	0.00	0.00	0.00
Profitability Margins
Gross Profit Margin	50.78%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	-69.13%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	-69.13%	0.00%	0.00%	0.00%	0.00%
Operating Profit Margin	-38.80%	0.00%	0.00%	0.00%	0.00%
Pretax Profit Margin	-39.52%	0.00%	0.00%	0.00%	0.00%
Net Profit Margin	-69.85%	0.00%	0.00%	0.00%	0.00%
Continuous Operations Profit Margin	-39.52%	0.00%	0.00%	0.00%	0.00%
Net Income Per EBT	176.74%	0.00%	0.00%	0.00%	0.00%
EBT Per EBIT	101.85%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	-18.57%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-17317.04%	0.00%	0.00%	0.00%	0.00%
Return on Capital Employed (ROCE)	237.60%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-13.33%	0.00%	0.00%	0.00%	0.00%
Return on Tangible Assets	-18.57%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	-2.79%	-	-	-	-
Efficiency Ratios
Receivables Turnover	0.00	0.00	0.00	0.00	0.00
Payables Turnover	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00
Asset Turnover	0.27	0.00	0.00	0.00	0.00
Working Capital Turnover Ratio	248.86	0.00	0.00	0.00	0.00
Cash Conversion Cycle	0.00	0.00	0.00	0.00	0.00
Days of Sales Outstanding	0.00	0.00	0.00	0.00	0.00
Days of Inventory Outstanding	0.00	0.00	0.00	0.00	0.00
Days of Payables Outstanding	0.00	0.00	0.00	0.00	0.00
Operating Cycle	0.00	0.00	0.00	0.00	0.00
Cash Flow Ratios
Operating Cash Flow Per Share	>-0.01	0.00	0.00	0.00	0.00
Free Cash Flow Per Share	>-0.01	0.00	0.00	0.00	0.00
CapEx Per Share	<0.01	0.00	0.00	0.00	0.00
Free Cash Flow to Operating Cash Flow	1.00	0.00	0.00	0.00	0.00
Dividend Paid and CapEx Coverage Ratio	-13.38K	0.00	0.00	0.00	0.00
Capital Expenditure Coverage Ratio	-13.38K	0.00	0.00	0.00	0.00
Operating Cash Flow Coverage Ratio	-1.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Sales Ratio	-3.07	0.00	0.00	0.00	0.00
Free Cash Flow Yield	-12.27%	0.00%	0.00%	0.00%	0.00%
Valuation Ratios
Price-to-Earnings (P/E) Ratio	-35.87	0.00	0.00	0.00	0.00
Price-to-Sales (P/S) Ratio	25.06	0.00	0.00	0.00	0.00
Price-to-Book (P/B) Ratio	-153.46	0.00	0.00	0.00	0.00
Price-to-Free Cash Flow (P/FCF) Ratio	-8.15	0.00	0.00	0.00	0.00
Price-to-Operating Cash Flow Ratio	-8.15	0.00	0.00	0.00	0.00
Price-to-Earnings Growth (PEG) Ratio	-0.36	0.00	0.00	0.00	0.00
Price-to-Fair Value	-153.46	0.00	0.00	0.00	0.00
Enterprise Value Multiple	-39.66	0.00	0.00	0.00	0.00
Enterprise Value	917.70K	0.00	0.00	0.00	0.00
EV to EBITDA	-39.66	0.00	0.00	0.00	0.00
EV to Sales	27.42	0.00	0.00	0.00	0.00
EV to Free Cash Flow	-8.92	0.00	0.00	0.00	0.00
EV to Operating Cash Flow	-8.92	0.00	0.00	0.00	0.00
Tangible Book Value Per Share	>-0.01	0.00	0.00	0.00	0.00
Shareholders’ Equity Per Share	>-0.01	0.00	0.00	0.00	0.00
Tax and Other Ratios
Effective Tax Rate	0.00	0.00	0.00	0.00	0.00
Revenue Per Share	<0.01	0.00	0.00	0.00	0.00
Net Income Per Share	>-0.01	0.00	0.00	0.00	0.00
Tax Burden	1.77	0.00	0.00	0.00	0.00
Interest Burden	0.57	0.00	0.00	0.00	0.00
Research & Development to Revenue	0.00	0.00	0.00	0.00	0.00
SG&A to Revenue	1.38	0.00	0.00	0.00	0.00
Stock-Based Compensation to Revenue	0.00	0.00	0.00	0.00	0.00
Income Quality	7.78	0.00	0.00	0.00	0.00

Currency in USD